Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Net Margin (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Net Margin for 15 consecutive years, with 11.13% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 1673.0% to 11.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.74% through Dec 2025, up 1202.0% year-over-year, with the annual reading at 8.74% for FY2025, 1202.0% up from the prior year.
  • Net Margin hit 11.13% in Q4 2025 for Ani Pharmaceuticals, down from 11.53% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 12.95% in Q1 2024 to a low of 39.93% in Q4 2021.
  • Historically, Net Margin has averaged 5.41% across 5 years, with a median of 0.69% in 2023.
  • Biggest five-year swings in Net Margin: plummeted -3358bps in 2021 and later surged 3499bps in 2022.
  • Year by year, Net Margin stood at 39.93% in 2021, then surged by 88bps to 4.93% in 2022, then surged by 112bps to 0.57% in 2023, then tumbled by -1085bps to 5.61% in 2024, then skyrocketed by 299bps to 11.13% in 2025.
  • Business Quant data shows Net Margin for ANIP at 11.13% in Q4 2025, 11.53% in Q3 2025, and 3.85% in Q2 2025.